30 results about "Thyroid function" patented technology

The invention discloses a traditional Chinese medicine composition for treating hyperthyroidism and a preparation method thereof, and relates to the technical field of traditional Chinese medicines. The traditional Chinese medicine composition for treating hyperthyroidism is prepared from cyclodextrin grafted modified hollow mesoporous organic silicon nanoparticles, traditional Chinese medicine ferment powder and a traditional Chinese medicine extracting solution, the cyclodextrin-grafted modified hollow mesoporous organic silicon nano-particles are used as a carrier, traditional Chinese medicine ferment powder and a traditional Chinese medicine extracting solution are loaded, the medicine concentration of a focus part is increased, traditional Chinese medicine ingredients are rapidly released through rapid response fracture of tetrasulfide bond functional groups, and the traditional Chinese medicine composition is prepared in an active targeting and fixed-point blasting mode. The bioavailability and the onset time of the medicine are improved, the leakage risk of the medicine is jointly reduced through the gating effect of cyclodextrin and responsive release of tetrasulfide bonds, synthesis of thyroid hormone is more thoroughly inhibited under the precise effect of high-concentration medicine and multi-target immunoregulation of traditional Chinese medicine, and the recurrence rate of hyperthyroidism is reduced.

The application relates to the technical field of ultrasonic image analysis, and discloses a thyroid nodule evaluation system based on ultrasonic images. The system obtains medical record data and medical examination data of a patient through a multidimensional acquisition module, classifies and forms a data set, analyzes the thyroid function state of each patient through an intelligent evaluation module, generates a function coefficient, analyzes the picture quality of each group of ultrasonic images again, generates corresponding detection data group Jcsj, establishes a unified evaluation standard, quickly screens out key frames from a large amount of ultrasonic image data, has high multidimensional integration efficiency, sets a fixed range threshold value for the intelligent evaluation module, analyzes and generates a nodule volume and a nodule score in combination with a medical data set, and in combination with the function coefficient, the detection data group and the nodule score, evaluates the risk grade of the thyroid nodule and the picture quality of the ultrasonic image of the patient, screens out key frames of the ultrasonic image, and outputs a treatment suggestion; and the intelligent evaluation has high precision.

Provided are a set of fully human TSH receptor (TSHR)-blocking monoclonal antibodies targeting a CHK36 homolog cluster, a preparation method therefor, and an application thereof. The method comprises the following steps: using flow cytometry to sort plasma cells and single memory B cells that specifically recognize TSHR in peripheral blood of a patient with a high titer of TSH-blocking antibodies (TBAb), performing in vitro cloning of antibody light and heavy chains and performing recombinant expression, and using hTSHR-CHO cells to perform screening and validation of antibody properties to obtain a blocking monoclonal antibody that specifically targets human TSHR. The fully human TSH receptor-blocking monoclonal antibodies specifically bind to a TSHR, and effectively block signal transduction after a TSH binds to a receptor, inhibit the synthetic secretion of thyroid hormones, and significantly reduce and inhibit TSHR expression and fibrosis in orbital fibroblasts of effector cells associated with thyroid-related ocular diseases. The fully human TSH receptor-blocking monoclonal antibodies have broad application prospects in the treatment of Graves' disease (GD) and other diseases caused by hyperthyroidism, such as thyroid eye disease (TED).

The present disclosure relates to the field of clinical detection technology, in particular, to the application of triiodothyronine autoantibody as a marker of thyroid dysfunction during cancer treatment. The present disclosure can help clinicians to judge the real thyroid function status of patients and improve the accuracy of diagnosis.

The invention discloses a novel serum metabolite composition based on dried blood spot detection and elaborates application of the serum metabolite composition as a marker in preparation of a congenital hypothyroidism diagnostic reagent or kit. The serum metabolite composition comprises thyroxine, 2-piperidone and phosphorylcholine PC (14: 0 / 20: 4). The serum metabolite composition can be used for screening and diagnosing patients with the congenital hypothyroidism, and has the characteristics of low detection cost, good repeatability and relatively high sensitivity and specificity.

The utility model discloses a thyroid function measuring and counting device which comprises a measuring instrument and a counter which are movably connected with each other, a lifting handle is fixedly connected to the center of the top of the measuring instrument, a display screen is arranged on the left portion of the front face of the measuring instrument, and a connecting block is arranged on the right portion of the surface of the measuring instrument. A butt joint block is fixedly connected to the upper portion of the back face of the connecting block, and a butt joint inserting groove is formed in the surface of the connecting block. According to the utility model, the butt joint block is arranged on the back surface of the counter, the butt joint block is inserted into the butt joint slot on the surface of the connecting block, and then the positioning insertion rod is inserted into the positioning hole, so that the counter is further fixed, the stability of the counter after being installed is ensured, and during the installation operation, the limiting stop block is blocked outside the storage groove, so that the counter is prevented from being damaged. And the first telescopic rod cannot move backwards, so that when people insert the counter, the connecting block cannot move backwards, and the installation work of people is further facilitated.

The present application relates to the technical field of traditional Chinese medicine, and in particular, to a traditional Chinese medicine composition, a method for preparing same, and use thereof in preparing a medicament for preventing and treating a thyroid disease. The traditional Chinese medicine composition consists of Ranunculi Ternati radix, Taraxaci herba, Cyperi rhizoma, and Semiaquilegiae radix. The method comprises: mixing and crushing formulation amounts of Ranunculi Ternati radix, Taraxaci herba, Cyperi rhizoma, and Semiaquilegiae radix; or extracting formulation amounts of Ranunculi Ternati radix, Taraxaci herba, Cyperi rhizoma, and Semiaquilegiae radix. The compounding of the four traditional Chinese medicines, Ranunculi Ternati radix, Taraxaci herba, Cyperi rhizoma, and Semiaquilegiae radix, can significantly treat hypothyroidism, thyroid nodules, and the like caused by insufficient thyroid hormones. Compared with the prior art, the traditional Chinese medicine composition features clear ingredients, good safety, and better therapeutic effects, providing technical support for the treatment of thyroid diseases with traditional Chinese medicines.

The present invention is based on the realization and verification that inhibition of Luteinizing hormone (LH) and / or luteinizing hormone / choriogonadotropin receptor (LHCGR) is useful in the treatment, alleviation or prevention of different medical states related to perimenopause and menopause in women or hypogonadism in men. Thus, an aspect of the present invention relates to LH and / or LHCGR inhibitors for use in the treatment of postmenopausal osteoporosis in a female subject. Another aspect relates to LH and / or LHCGR inhibitors for use in the reduction of fat mass in a postmenopausal female subject. A further aspect relates to LH and / or LHCGR inhibitors for use in the treatment, hypergonadotropic hypogonadism in a male subject. In addition, another aspect relates to LH and / or LHCGR inhibitors for use in the treatment of symptoms of perimenopause and / or postmenopause such as hot flashes, night sweats, osteoporosis, weight gain, hypothyroidism, conversion of T4 to T3, and / or primary hyperparathyroidism.

Hyperthyroid diarrhea refers to hyperthyroid diarrhea, which is mostly intractable diarrhea, due to excessive thyroid hormone causing increased intestinal peristalsis excitability and diarrhea when the thyroid function is increased, which is caused by endocrine metabolic disorder leading to gastrointestinal function disorder. The present application studies and observes the treatment effect of kaempferol coupling derivative JC-1 on diarrhea of hyperthyroid model mice, and provides a new drug treatment option for diarrhea type colon dysfunction.

Provided are a group of fully human thyrotropin receptor (TSHR) (TSH receptor, TSHR) blocking monoclonal antibodies belonging to a SH1 homocluster, a preparation method therefor, and a use thereof. The method comprises the following steps: using flow cytometry to sort plasma cells and individual memory B cells, which specifically recognize TSHR, from peripheral blood of a patient having a high TSH receptor blocking antibody (TBAb) titer, cloning antibody light and heavy chains in vitro, followed by recombinant expression, and performing antibody characteristic screening and verification by using hTSHR-CHO cells, thereby obtaining blocking monoclonal antibodies that specifically target human TSHR. The fully human TSH receptor blocking monoclonal antibodies can specifically bind to TSHR, thereby enabling effective blockage of signal transduction after TSH binds to the receptor, inhibiting the synthesis and secretion of thyroid hormones, and significantly reducing and suppressing the expression of TSHR and fibrosis in orbital fibroblasts, the effector cells in thyroid-related eye diseases. The present invention has broad application prospects in the treatment of Graves' diseases and diseases caused by hyperthyroidism, such as thyroid eye diseases.

This disclosure broadly relates to the field of clinical testing technology, and more specifically, to the application of thyroxine autoantibodies as biomarkers of thyroid dysfunction during cancer treatment. This disclosure can help clinicians determine a patient's true thyroid function status and improve diagnostic accuracy.

This invention provides an intelligent auxiliary diagnostic system for thyroid function based on small-sample ultrasound images, belonging to the field of auxiliary diagnostic technology. The system first acquires a thyroid dataset consisting of n cases to construct a small-sample thyroid ultrasound image dataset; then, it constructs a thyroid function classification model based on the EfficientNet-B0 model; this classification model adds a CBAM attention module, a layer normalization layer, an embedding layer, and a Dropout layer to the original EfficientNet-B0 model; the classifier uses independent linear layers; the thyroid function classification model is then trained based on the thyroid ultrasound image dataset; finally, unlabeled thyroid ultrasound images are acquired, and the trained thyroid function classification model is used to classify thyroid function. This system can achieve comprehensive screening of thyroid function.

Wearable Device for Indirect Thyroid Function Assessment

Described herein are compositions, pharmaceutical compositions, kits, and methods of use relating to anti-Dio3os antisense RNA. In embodiments, antisense Dio3os compositions, kits, and methods are described to improve symptoms of osteoporosis, for example, osteoporosis induced by a disorder characterized by a thyroid hormone imbalance (i.e., hyperthyroidism or hypothyroidism). In embodiments, antisense Dio3os compositions, kits, and methods are described to improve sensitivity of cancer cells to anti-cancer therapeutics, for example, sensitivity of ER+ breast cancer or other breast cancer cells, thyroid cancer cells, prostate cancer cells, hepatocellular cancer cells, pancreatic cancer cells, and ovarian cancer cells that are sensitized or otherwise non-responsive to cancer therapeutics (for example, aromatase inhibitors or HDAC inhibitors). Combination therapies are also contemplated utilizing antisense RNA according to the present disclosure and other drugs, for example, thyroid and anti-cancer medications.

The invention relates to a children hypothyroidism curative effect dynamic monitoring method and system fusing growth and development data. The method comprises the following steps: acquiring growth and development data of a target child patient and extracting key growth and development characteristics to obtain growth and development characteristic data; performing growth and development change trend analysis to obtain growth and development time sequence change trajectory data; inputting the trajectory data into a preset growth prediction model to deduce a future growth and development state to obtain growth and development prediction data; calculating a multi-dimensional deviation between the growth and development time sequence data and the prediction data to obtain growth and development deviation degree data; acquiring thyroid function test index data of the target child patient, and performing correlation analysis and curative effect grade mapping on the thyroid function test index data and the deviation degree data to obtain a curative effect monitoring result. By adopting the method, the problems that traditional monitoring lacks dynamic modeling, multi-source data association is insufficient and curative effect evaluation lags subjective can be solved, dynamic quantitative evaluation of the curative effect is realized, and a reliable basis is provided for clinical treatment adjustment.

This invention discloses a traditional Chinese medicine composition, its preparation, and its application for treating solid and cystic thyroid nodules caused by liver stagnation and spleen deficiency. The traditional Chinese medicine composition of this invention, by weight, comprises the following raw materials: 20-30 parts of Prunella vulgaris, 20-30 parts of Taraxacum mongolicum, 10-15 parts of Salvia miltiorrhiza, 6-9 parts of Bupleurum chinense (processed with vinegar), 9-10 parts of Citrus aurantium (fried), 9-12 parts of Paeonia lactiflora, 10-15 parts of Cyperus rotundus, 20-30 parts of Coix lacryma-jobi, 15-20 parts of Fritillaria thunbergii, 20-30 parts of pearl powder, and 20-30 parts of oyster shell. This invention also discloses the preparation of this traditional Chinese medicine composition. The traditional Chinese medicine composition and its preparation of this invention can effectively shrink thyroid nodules and improve symptoms such as neck fullness, pulling sensation, foreign body sensation in the throat, occasional stabbing pain in the front of the neck, irritability or depression, fatigue, loose stools, and poor sleep in patients with nodules caused by liver stagnation and spleen deficiency, without affecting thyroid function.

The invention provides a thyroid-related eye disease mouse model evaluation method. The thyroid-related eye disease mouse model evaluation method comprises the following steps: S1, appearance phenotype evaluation; s2, thyroid function index evaluation; s3, carrying out iconography evaluation; s4, performing immunological phenotype evaluation; and S5, carrying out histopathologic evaluation. Compared with a traditional research method only paying attention to single eye phenotype or single histological change, the thyroid-related eye disease mouse model evaluation method provided by the invention comprehensively reflects disease characteristics of a TAO mouse model from five dimensions of appearance phenotype, thyroid function, immune phenotype, histopathology and iconography; multi-dimensional comprehensive evaluation of the TAO mouse model is realized, and a scientific, comprehensive and standardized evaluation method is established.

The invention discloses a THR-beta receptor agonist as well as a preparation method and a use method thereof. The invention provides a compound as shown in a formula (I), and pharmaceutically acceptable salt or stereoisomer thereof. The agonist provided by the invention has relatively good THR-beta agonistic activity and selectivity and strong liver targeting, and can be applied to metabolic diseases (such as non-alcoholic steatohepatitis (NASH), hepatic steatosis, hyperlipidemia and obesity), cardiovascular diseases (such as atherosclerosis) and thyroid diseases (such as hypothyroidism and thyroid cancer).

The application belongs to the field of biomedicine, and particularly relates to application of a PCSK9 inhibitor in preparation of a drug for treating hypothyroidism with hyperlipidemia. In view of the problem that statins are prone to cause early liver and kidney function damage in the process of reducing lipids in the population with hypothyroidism and hyperlipidemia, the application proves through a mouse model experiment that the PCSK9 inhibitor (alirocumab) has a better effect on reducing LDL-C and VLDL-C in the mouse model, has no influence on thyroid function, can reduce liver and kidney damage, relieve inflammation and oxidative stress, and remodel lipid spectrum. For the population with hypothyroidism and hyperlipidemia, the PCSK9 inhibitor (alirocumab) has both efficacy and safety compared with statins, and has a good clinical application prospect.

The invention relates to the technical field of traditional Chinese medicine preparations, and particularly discloses a thyroid function regulation and control preparation based on an astragalus membranaceus fermentation extract and a preparation method thereof, and the preparation is technically characterized in that the preparation takes an extract obtained after astragalus membranaceus is fermented by specific microorganisms (such as lactobacillus plantarum) as an active ingredient. Systematic iodine deficiency rat model experiments prove that the fermentation extract has obviously better effects in the aspects of improving thyroid functions and forms (such as adjusting FT3, FT4, TSH and TPO-Ab), enhancing body antioxidant ability (such as improving activity of SOD and CAT of hippocampus and liver) and improving learning and memory behaviors than a traditional astragalus extract. The invention provides an effective scheme for developing an innovative traditional Chinese medicine preparation for comprehensively preventing and treating the iodine deficiency thyroid disease and complications thereof.

This invention provides a traditional Chinese medicine preparation for treating Hashimoto's thyroiditis and its preparation method, belonging to the field of traditional Chinese medicine pharmaceutical technology. The preparation is made from Curcuma zedoaria, oyster shell, Eclipta prostrata, Ligustrum lucidum, Sargassum, processed Aconitum carmichaelii, Cremastra appendiculata, Duchesnea indica, Hedyotis diffusa, Artemisia capillaris, Oroxylum indicum, and cinnamon. The formula is meticulously formulated, closely addressing the core pathogenesis of Hashimoto's thyroiditis: "phlegm and blood stasis, spleen and kidney deficiency, and nutritional imbalance." It focuses on "eliminating masses and dispersing nodules, promoting qi and blood circulation," fully embodying the TCM diagnostic and treatment approach of "differentiating syndromes and treating accordingly, addressing both the root cause and symptoms." This invention's preparation has a good therapeutic effect on Hashimoto's thyroiditis, effectively improving thyroid autoimmune disorders, regulating thyroid function, and alleviating symptoms of local thyroid inflammation in experimentally induced Hashimoto's thyroiditis rats. Further clinical observation studies have found that this preparation significantly improves the overall effective rate of clinical treatment for Hashimoto's thyroiditis patients, providing a new approach to the treatment of this condition.

The application belongs to the field of data model processing, and discloses a liver disease thyroid function abnormality early warning system based on machine learning; data is collected, and the collected data is marked through prior processing; potential noise data is subjected to self-cleaning processing to obtain verification data; a causal path is pre-constructed according to a false alarm signal scene, a liver-thyroid cross-organ causal network is formed by comprehensively integrating the causal path, and time sequence analysis of the verification data is matched with the causal path to form a generated causal feature vector; a denoising engine is deployed to re-optimize the causal feature vector, a fusion feature vector is obtained, and an edge device is updated through global learning; the contribution of the fused feature vector is quantified, hierarchical early warning is performed through judgment, and liver disease thyroid function abnormality early warning based on machine learning is realized.

The invention belongs to the field of data model processing, and discloses a hepatopathy thyroid function abnormity early warning system based on machine learning. Comprising the following steps: collecting data, marking the collected data through prior processing, and performing self-cleaning processing on the marked potential noise data to obtain verification data; a causal path is pre-constructed according to the false alarm signal scene, a liver-thyroid cross-organ causal network is formed by integrating the causal path, and time sequence analysis of verification data is matched with the causal path to form and generate a causal feature vector; deploying a denoising engine to re-optimize the causal feature vector to obtain a fusion feature vector, and updating edge end equipment through global learning; and carrying out contribution degree quantification on the fused feature vectors, and carrying out grading early warning after judgment to realize liver disease thyroid function abnormality early warning based on machine learning.

The present application relates to the technical field of medical data processing, in particular to a system for evaluating glutamic oxalacetic transaminase value, which comprises a data acquisition and standardization module, a feature engineering and proxy variable construction module, a multi-path joint regression prediction module, an interpretable risk stratification output module and a continuous learning and federal deployment module. The system takes blood lipids, body weight / body mass index and diastolic blood pressure as input features, innovatively constructs a thyroid function proxy score as an intermediate latent variable, realizes rapid regression prediction of glutamic oxalacetic transaminase value through a three-path parallel sub-network hierarchical fusion network, outputs point estimates and Bayesian confidence intervals; at the same time, based on the SHAP algorithm, an interpretable feature attribution report and a four-level risk stratification result are output, and multi-institutional compliance collaborative training is realized through horizontal federated learning and differential privacy mechanism.

The invention relates to the technical field of traditional Chinese medicines, in particular to application of a traditional Chinese medicine composition in preparation of a medicine for preventing and / or treating thyroid diseases. Experiments show that the traditional Chinese medicine composition has a good treatment effect on thyroid diseases. The traditional Chinese medicine composition can reduce the thyroid quality and relative quality of rats, obviously improve the content of TSH, FT3 and FT4 in serum of the rats, regulate the thyroid function, promote apoptosis of thyroid cells, inhibit proliferation, recover the balance of thyroid proliferation and apoptosis, relieve thyroid injury, reduce the thyroid inflammation level and effectively improve thyroid diseases.

The invention provides a traditional Chinese medicine compound preparation for auxiliary nursing of hashimoto thyroiditis, and relates to the technical field of traditional Chinese medicine pharmacy. The traditional Chinese medicine compound preparation is prepared from the following traditional Chinese medicinal materials: resina liquidambaris, homalomena occulta, sword brake herb, walnut twig, resina erythrinae, siberian elm bark, polygonum cuspidatum, red-knees herb, perfoliote knotweed herb, akebia fruit, oroxylum indicum, semen brassicae, kadsura longipedunculata, rhizoma dioscoreae nipponicae, ginseng leaf and rhizoma zingiberis. According to the traditional Chinese medicine compound preparation, the autoantibody titers of HT model rat serum TPOAb and TgAb can be effectively reduced, thyroid function indexes FT3, FT4 and TSH are effectively improved, and meanwhile generation and activity of HT model serum inflammatory factors can be effectively inhibited. The traditional Chinese medicine compound preparation disclosed by the invention has a relatively good treatment effect in the aspects of inhibiting autoantibody generation and reducing thyroid damage and can be used for effectively treating hashimoto thyroiditis by inhibiting inflammatory response. The traditional Chinese medicine compound preparation disclosed by the invention is expected to be further developed and researched as a medicine for treating or assisting in treating hashimoto thyroiditis.

The invention relates to the field of determining the tissue thyroid hormone status of a subject. A minimally-invasive approach using hair follicle markers to assess tissue TH economy is pro-vided. A classification model fit to categorize subjects into tissue hypothyroid, euthyroid and hyperthyroid categories is provided. The method is suitable to determine tissue thyroid hormone status in patients treated with amiodarone.

Provided are a group of SH23 homologous cluster fully-human thyrotropin receptor (TSH receptor, TSHR)-blocking monoclonal antibodies, a preparation method therefor and the use thereof. The method comprises the following steps: by means of flow cytometry, sorting plasma cells and memory single B cells that specifically recognize TSHR from the peripheral blood of a patient with a high TSH receptor-blocking antibody (TSH-stimulating blocking antibody, TBAb) titer, performing in-vitro cloning of light and heavy chains of the antibody, performing recombination and expression, and carrying out antibody property screening and verification by using TSHR-CHO cells to obtain a blocking monoclonal antibody that specifically targets human TSHR. The fully-human TSH receptor blocking monoclonal antibodies can specifically bind to TSHR, can effectively block the signal transduction after TSH binds to a receptor, and have good inhibitory activity in in vitro and in vivo experiments, and therefore have broad application prospects in the treatment of diseases, such as Graves' disease (GD) and hyperthyroidism-induced diseases, such as thyroid eye disease (TED).

This disclosure relates to compositions and methods for treating hypothyroidism. Wherein a method of treating a patient for hypothyroidism, comprises: a) obtaining a sample from a patient containing DNA; b) determining a number of pre-defined single nucleotide polymorphisms (SNPs) contained in the DNA of the sample; c) administering to the patient a therapeutically effective amount of levothyroxine.